摘要
目的探讨行为激活疗法联合奥氮平对难治性抑郁症患者血清脑源性神经营养因子(BDNF)及生活质量的影响。方法选取2017年4月~2019年6月本院收治的74例难治性抑郁症患者,按随机数字表法分成两组,对照组37例予奥氮平治疗,观察组37例予行为激活疗法联合奥氮平治疗。治疗8周后,比较两组患者抑郁症状改善情况、临床疗效、血清BDNF水平及生活质量。结果两组治疗后HAMD-17评分均较治疗前显著降低(P<0.05),血清BDNF水平较治疗前显著增高(P<0.05);而观察组治疗各时期HAMD-17评分均明显低于同期对照组(P<0.05),血清BDNF水平均明显高于对照组(P<0.05);观察组临床疗效明显优于对照组(P<0.05),观察组临床总有效率为64.86%,明显高于对照组(40.54%)(P<0.05);两组患者GQOLI-74评分均呈显著性增高(P<0.05),治疗后观察组GQOLI-74评分明显高于对照组(P<0.05)。结论行为激活疗法联合奥氮平能显著改善难治性抑郁症患者的抑郁症状,提高临床疗效,上调血清BDNF表达水平,提高患者生活质量,疗效确切,值得临床推广。
Objective To explore the effect of behavior activation therapy combined with olanzapine on serum brain-derived neurotrophic factor(BDNF)and quality of life in patients with refractory depression.Methods 74 patients with refractory depression admitted to Wenzhou Seventh People's Hospital between April 2017 and June 2019 were divided into observation group and control group using random number table method,with 37 cases in each group.The control group was treated with olanzapine,and the observation group was treated with behavior activation therapy combined with olanzapine.After 8 weeks of treatment,the improvement of depressive symptoms,clinical efficacy,serum BDNF level and quality of life were compared between the two groups.Results After treatment,the Hamilton Depression Scale(HAMD-17)score of the two groups were significantly lower than those before treatment(P<0.05),and the serum BDNF level were significantly higher than those before treatment(P<0.05);while the HAMD-17 score of the observation group was significantly lower than that of control group in the same period,and the level of serum BDNF was significantly higher than that in the control group(P<0.05).The clinical efficacy of the observation group was significantly better than that of the control group(P<0.05).The total clinical efficacy of the observation group was 64.86%,which was significantly higher than that of the control group(40.54%)(P<0.05).The Generic Quality of Life Inventory-74(GQOLI-74)scores of the two groups were significantly higher as compared to those before the treatment(P<0.05),and the GQOLI-74 scores of the observation group were significantly higher than that of the control group(P<0.05).Conclusion Behavior activation therapy combined with olanzapine can significantly improve the depressive symptoms and clinical efficacy of patients with refractory depression,up-regulate the expression level of serum BDNF,improve the quality of life of patients,which is worthy of clinical promotion.
作者
赵飞飞
金益昌
陈策
涂献珠
ZHAO Feifei;JIN Yichang;CHEN Ce;TU Xianzhu(Wenzhou Seventh People's Hospital,Wenzhou325000,China;Zhejiang University of Traditional Chinese Medicine,Hangzhou310053,China;Department of Orthopaedics,906 Hospital of the PLA,Wenzhou325000,China)
出处
《中国现代医生》
2020年第23期103-106,共4页
China Modern Doctor
基金
浙江省医药卫生科技计划项目(2019KY669)。
关键词
行为激活疗法
奥氮平
难治性抑郁症
脑源性神经营养因子
生活质量
Behavior activation therapy
Olanzapine
Refractory depression
Brain-derived neurotrophic factor
Quality of life
